AL-001 (Anlong) Drug Asset Due Diligence Report 2026

This AL-001 (Anlong) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

192

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether AL-001 (Anlong) can convert its AAV based gene therapy profile and VEGF biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	AL-001 (Anlong) (query alias: AL-001 (Anlong))
Modality / target	AAV based gene therapy; VEGF; VEGF inhibitors
Highest global status	Phase 2
Originator	Beijing Anlong Biopharmaceutical Co., Ltd.
Active developers	Beijing Anlong Hopson Pharmaceutical Co., Ltd., Beijing Anlong Biopharmaceutical Co., Ltd.

The MCP disease footprint includes Diabetic Retinopathy, Wet age-related macular degeneration. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTR20261912	Phase 2	Not yet recruiting	40	Primary endpoint not disclosed in English source
NCT06839339	Phase 2	Not yet recruiting	40	Primary endpoint not disclosed in English source
NCT06707753	Phase 1/2	Active, not recruiting	21	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

AL-001 (Anlong) addresses Diabetic Retinopathy, Wet age-related macular degeneration. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—AAV based gene therapy—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 192 matched transaction record(s) under the scope “target-level comparable: VEGF.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: VEGF records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-09-14	Bio Usawa and Axmed Partner to Expand Access to Affordable Biologic Medicines Across Africa	Approved	Financial terms not disclosed
2026-08-19	Senju Pharmaceutical had entered into an agreement to commercialize Sam Chun Dang Pharm ' SCD-411 for glaucoma	Approved	Financial terms not disclosed
2026-07-29	Mabwell Established a Licensing and Commercialization Agreement of Aflibercept Biosimilar for GCC Market	NDA/BLA	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Engineered nucleic acid regulatory element and methods of uses thereof”. The milestone feed surfaced a patent-application signal described as “Fully-human post-translationally modified antibody therapeutics”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION